Trevi Therapeutics, Inc.
Trevi Therapeutics, Inc. (TRVI) Company Profile & Overview
Explore Trevi Therapeutics, Inc.’s business operations, leadership, sector classification, and key company facts including IPO date, industry, and contact details.
Trevi Therapeutics, Inc. (TRVI) Company Profile & Overview
Trevi Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of Haduvio to treat serious neurologically mediated conditions. The company is developing Haduvio, an oral extended-release formulation of nalbuphine, which is in phase IIb/III clinical trial for the treatment of chronic pruritus, chronic cough in patients with idiopathic pulmonary fibrosis. It has a license agreement with Endo Pharmaceuticals Inc. to develop and commercialize products incorporating nalbuphine hydrochloride in any formulation. The company was incorporated in 2011 and is headquartered in New Haven, Connecticut.